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Abstract
Background: Whenever technically feasible and oncologically justified, nephron-sparing surgery is the current
standard of care for localized renal cell carcinomas (RCC). The main complications of partial nephrectomy,
especially for large and centrally located tumors, are urinary leakage and parenchymal bleeding. We prospectively
evaluated the pros and cons of using porcine small intestinal submucosa (SIS, Surgisis®) to close the renal defect
after nephron-sparing surgery.
Methods: We used Surgisis® (Cook medical, Bloomington, IN, USA) to secure and compress the capsular defect after
tumor resection in 123 patients submitted to 129 partial nephrectomies between August 2003 and February 2011.
Results: The median tumor size was 3.7 cm (range 1.1-13.0 cm). Procedures were performed with cold ischemia in
24 cases (18.2%), with warm ischemia in 46 (35.6%), and without ischemia in 59 cases (44.8%). In the total group of
patients, 4 (3.1%) developed urinary fistula, and only 2 (1.6%) required postoperative transfusions due to
hemorrhage after the application of the small intestinal submucosa membrane.
Conclusion: Small intestinal submucosa is an easy-to-use biomaterial for preventing complications such as
postoperative bleeding and urinary fistula in nephron-sparing surgery, especially in cases where tumor excision
causes significant renal capsular and/or renal pelvic defects.
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Background
Whenever technically feasible and oncologically justified,
nephron-sparing surgery is the current standard of care
for localized renal tumors of any size [1]. Its high status
is based on substantial evidence from numerous studies
confirming that postoperative morbidity such as cardio-
vascular disease, diabetes and renal failure can thus be
avoided without significantly increasing the risk of tumor
recurrence [2-5]. Nevertheless, the proportion of
nephron-sparing interventions in most urological centers
is still well below 50% [6]. One reason for this discre-
pancy may be that partial nephrectomy is sometimes
technically demanding and occasionally involves signifi-
cant complications in a percentage of patients that merits
attention. The most prevalent adverse outcomes after
partial nephrectomy include urinary leakage/fistula (1.3 -
9.1%) and parenchymal bleeding (0 - 7.9%) with higher
complication rates after excision of larger tumors [7-15].
Porcine small intestinal submucosa (SIS, Surgisis®) is a
natural acellular collagen-based biomaterial. The Surgi-
sis® membrane is increasingly used for different pur-
poses in abdominal surgery [16,17], gynecology and
obstetrics [18], and, more recently, urology [19-21].
We describe the use of this small intestinal submucosa
membrane to optimize and facilitate closure of the col-
lecting system and particularly the parenchymal defect
and to minimize parenchymal bleeding after partial
nephrectomy in a series of 123 patients.
Materials and methods
Surgisis® (Cook medical, Bloomington, IN, USA) was
used to close and secure the capsular defect in 123
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patients who underwent 129 partial nephrectomies from
August 2003 to March 2011 (Figure 1).
After excising the tumor with a normal tissue margin
using a Leriche dissector for blunt dissection as
described earlier [20], we ligated or clipped visible blood
vessels within the renal defect. The collecting system, if
necessary, was closed with monofilament sutures. A pye-
lostoma or mono-J catheter was inserted in cases with
large collecting system defects. The renal defect was
then treated with a hemostyptic agent such as TachoSil®
(Nycomed, Unterscheissheim, Germany), FloSeal® (Bax-
ter, Deerfield, IL, USA), and/or Tabotamp® (Johnson &
Johnson Medical GmbH, Norderstedt, Germany). The
hydrated Surgisis® membrane was then cut into shape
and tightly fixed over the parenchymal defect with a 3-0
Vicryl a running suture mimicking the fixation of a
drumhead (Figure 2). Suturing of the renal surface was
kept superficial, since deep stitches cause additional par-
enchymal scarring. If FloSeal® was used for hemostasis,
it was injected into the parenchymal defect beneath the
Surgisis® tissue graft just before finishing the running
sutures securing the membrane. A percutaneous drain
was placed to monitor postoperative bleeding and urin-
ary leakage.
Results
Depending on the tumor size and/or location within the
kidney, procedures were performed with cold ischemia
in 24/129 cases (18.6%), with warm ischemia in 46/129
(35.6%), and without ischemia in 59/129 (45.8%) cases.
The median tumor size was 3.7 cm (range 1.1-13.0 cm).
Thirty-one lesions were benign, and 98 were classified
as RCC. In the latter group, staging revealed 94 pT1
tumors, 1 pT2 tumor, 2 pT3 tumors, and 1 pT4 tumor.
It generally took about 5-10 min to fix the Surgisis®
membrane over the renal defect.
Four patients (3.1%) developed postoperative urinary
fistulas, three of whom had tumors > 4 cm. However,
the insertion of Mono-J and/or Double-J catheters
achieved fistula closure without further intervention.
Two patients (1.6%) with significant postoperative bleed-
ing required reoperation or coiling of a segmental artery.
The reason for reoperation was a bleeding venotomy
suture line following in situ cold perfusion immediately
after the primary surgical procedure.
Figures 3 and 4 show pictures of a patient with
chronic renal failure who suffered from a large renal cell
carcinoma and was treated by partial nephrectomy. The
renal defect was easily closed and controlled using a
Surgisis® membrane.
Discussion
The incidence of localized renal cell carcinoma (RCC)
continues to increase; these tumors account for up to
81% of all RCC at diagnosis, at least in urban areas [6].
Nephron-sparing surgery is now the recommended
Figure 1 Schematic illustration of a partial nephrectomy and subsequent application of Surgisis® to optimize and facilitate the closure
of the renal defect: A) Tumor in place, B) kidney after tumor excision, C) creation of a phantom or placeholder volume using a hemostyptic
agent, D) optimum hemostasis after fixation of Surgisis® to apply homogeneous pressure onto the resection ground.
Figure 2 Schematic illustration of the running suture technique
mimicking the fixation of a drumhead to fix the Surgisis®
membrane to the renal capsule over the renal defect.
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standard of care for localized resectable RCC of any size
[1,22,23], although this is not yet reflected in routine
clinical practice. A recently published population-based
case-control study conducted by Miller et al. [6] in
metropolitan Detroit and Chicago showed that until
2007 almost 80% of patients with localized RCC were
treated by radical and only 20% by partial nephrectomy.
This is alarming, since several trials have clearly demon-
strated that total removal of the kidney was associated
with a higher risk of postoperative renal failure [2], car-
diovascular disease [3], diabetes [4] and even early death
[3,5].
While it is generally agreed that a nephron-sparing
approach should be adopted for surgical treatment of
localized RCC, the optimal technique (open, laparo-
scopic, or robot-assisted) is still under debate and prob-
ably of secondary importance [10,24,25].
Despite the steadily decreasing incidence of postopera-
tive adverse events after partial nephrectomy, mostly
due to the development of novel hemostyptic agents, a
significant number of complications still occur. In a
2007 study on partial nephrectomy in 1,800 patients
(median tumor size 3 cm), Gill et al. [10] reported that
5-9% had postoperative urological complications, includ-
ing hemorrhage (2-4%), urine leakage (2-3%), and renal
failure (1-2%). Subsequent invasive procedures were
required in 4-7% of all patients. Moreover, the compli-
cation rate seems to increase with the size of the defect
after tumor excision [7].
Here we describe an improved technique for parench-
ymal defect closure in which the use of a modern
hemostyptic agent is combined with Surgisis® mem-
brane placement to secure and compress the defect
without causing significant additional renal parenchymal
injury or scarring. In contrast to conventional surgical
techniques for hemostasis, the use of a Surgisis® mem-
brane does not compromise blood flow in the parenchy-
mal resection margin, since no parenchymal tissue has
to be gathered or folded. The running suture technique
mimicking the fixation of a drumhead (Figure 2) addi-
tionally enables maximal stability and prevents tearing
of the suture from the renal capsule [26]. Another great
advantage of this technique is the establishment of a
phantom or placeholder volume beneath the membrane
(Figure 1) which enables the establishment of homoge-
nous pressure on the resection area. After > 120 appli-
cation, we feel that this can most easily be achieved
using Flowseal because of its swell volume of approxi-
mately 20% [27], which is achieved within only a few
minutes and leads to an additional physical restriction
of blood flow.
Significant postoperative bleeding from the tumor base
occurred in 0.8% and urinary fistulas in 3.1% of our
patient population, only. Thus the procedure described
here may further reduce the complication rate of partial
nephrectomy and helps to minimize the loss of func-
tional renal tissue. We also feel that the use of this sim-
plified and safe surgical technique could further increase
the proportion of patients undergoing nephron-sparing
surgery, which has surely become one of the most
important goals in the treatment of localized RCC.
Also noteworthy in this context is a recent study by
O’Connor et al. [21] who reported that one of their 24
patients submitted to partial nephrectomy using a Surgi-
sis® membrane had to undergo a second partial
nephrectomy for a new ipsilateral tumor 9 months after
the original procedure. Intraoperatively, the reoperated
kidney appeared absolutely normal with total incorpora-
tion of Surgisis® into the collecting system and parench-
yma. As in animal models, this membrane appeared to
have been replaced by native tissue with no significant
Figure 3 Large clear cell renal cell carcinoma prior to nephron-
sparing surgery in a patient with chronic renal failure.
Figure 4 Hydrated porcine small intestinal submucosa
(Surgisis®) trimmed and tacked in place over the large renal
parenchymal defect (cf. Figure 3), fixed with two running
sutures.
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local fibrosis [28]. This may prove beneficial, particularly
in cases of angiomyolipoma or familial renal tumors
that may require multiple, ipsilateral partial nephrec-
tomies [21].
A disadvantage of the surgical technique described
here is the expense involved; we pay approximately €
204 for one Surgisis® membrane. In addition, the suit-
ability of this technique for endoscopic tumor enuclea-
tions still has to be assessed.
Conclusion
Surgisis® membrane placement combined with the use
of a conventional hemostyptic agent is effective, free
from side effects, and very easy to perform; it is indi-
cated especially for safe closure of large renal capsular
defects. Therefore, currently a clinical trial is being
planned in cooperation with the German Renal Cell
Cancer Network, in which the application of Surgisis®
will be evaluated vs. standard closure of renal defects for
tumors with a diameter > 4 cm. We do hope that the
establishment of novel techniques such as the applica-
tion of Surgisis® will further increase the proportion of
patients undergoing nephron-sparing surgery.
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